An Overview of Organ-Specific Autoimmune Diseases Including Immunotherapy

Immunological Investigations

Volumn 44, Issue 8, 2015, Pages 803-816

  Mastrandrea, Lucy D ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Autoimmunity; biologics; cytokine; diabetes; immunity; T cell; treatment

Indexed keywords

AUTOANTIBODY; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; THYROID HORMONE; THYROTROPIN; ANTIINFLAMMATORY AGENT; BIOLOGICAL FACTOR; CYTOKINE;

ACUTE PHASE RESPONSE; ADAPTIVE IMMUNITY; ANAPHYLAXIS; ANTIBODY SPECIFICITY; AUTOIMMUNE DISEASE; AUTOIMMUNE THYROIDITIS; AUTOIMMUNITY; B LYMPHOCYTE; CELL FUNCTION; CHILL; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; FEVER; FLU LIKE SYNDROME; HEMOLYTIC ANEMIA; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOTHERAPY; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; MOLECULAR MIMICRY; MYASTHENIA GRAVIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATIC HEART DISEASE; SIGNAL TRANSDUCTION; SUBSTITUTION THERAPY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THYROID FUNCTION; ANIMAL; AUTOIMMUNE DISEASES; DRUG EFFECTS; IMMUNITY; IMMUNOLOGY; METABOLISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; BIOLOGICAL FACTORS; CYTOKINES; HUMANS; IMMUNITY; ORGAN SPECIFICITY; T-LYMPHOCYTES;

EID: 84948184413     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.3109/08820139.2015.1099409     Document Type: Review

References (35)

1. Aaltonen J, Bjorses P, Perheentupa J, et al. (1997). An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet, 17, 399-403
2. Ambery P, Donner TW, Biswas N, et al. (2014). Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study. Diabet Med, 31, 399-402
3. Argiles J, Lopez-Soriano J, Lopez-Soriano F. (1994). Cytokines and diabetes: The final step? Involvement of TNF-alpha in both type I and type II diabetes mellitus. Horm Metab Res, 26, 447-9
4. Atkinson MA. (2012). The pathogenesis and natural history of type 1 diabetes. Cold Spring Harb Perspect Med, 2, a007641118
5. Bailey-Bucktrout SL, Martinez-Llordella M, Zhou X, et al. (2013). Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity, 39, 949-62
6. Berentsen S, Sundic T. (2015). Red blood cell destruction in autoimmune hemolytic anemia: Role of complement and potential new targets for therapy. BioMed Res Int, 2015, 11
7. Bluestone JA. (2011). Mechanisms of tolerance. Immunol Rev, 241, 5-19
8. Bratland E, Husebye ES. (2011). Cellular immunity and immunopathology in autoimmune Addisons disease. Mol Cell Endocrinol, 336, 180-90
9. Cooper GS, Bynum MLK, Somers EC. (2009). Recent insights in the epidemiology of autoimmune diseases: Improved prevalence estimates and understanding of clustering of diseases. J Autoimmuni, 33, 197-207
10. Dabelea D, Mayer-Davis EJ, Saydah S, et al. (2014). Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA, 311, 1778-86
11. Gerber MA, Baltimore RS, Eaton CB, et al. (2009). Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: A scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics. Circulation, 119, 1541-51
12. Keane J, Gershon S, Wise RP, et al. (2001). Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. NEngl J Med, 345, 1098-104
13. Knight D, Trinh H, Le J, et al. (1993). Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol, 30, 1443-53
14. Kremer JM, Genant HK, Moreland LW, et al. (2006). Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial. Ann Intern Med, 144, 865-76
15. Lee J-H, Slifman NR, Gershon SK, et al. (2002). Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept. Arthritis Rheum, 46, 2565-70
16. Maheshwari R, Weis E. (2012). Thyroid associated orbitopathy. Indian J Ophthalmol, 60, 87-93
17. Mastrandrea L, Yu J, Behrens T, et al. (2009). Etanercept treatment in children with new-onset type 1 diabetes: Pilot randomized, placebo-controlled, double-blind study. Diabetes Care, 32, 1244-9
18. McLeod DA, Cooper D. (2012). The incidence and prevalence of thyroid autoimmunity. Endocrine, 42, 252-65
19. Moghadam-Kia S, Werth VP. (2010). Prevention and treatment of systemic glucocorticoid side effects. Int J Dermatol, 49, 239-48
20. OGarra A, Vieira P. (2004). Regulatory T cells and mechanisms of immune system control. Nat Med, 10, 801-5
21. Orban T, Sosenko JM, Cuthbertson D, et al. (2009). Pancreatic islet autoantibodies as predictors of type 1 diabetes in the diabetes prevention Trial-Type 1. Diabetes Care, 32, 2269-74
22. Ortonne JP. (2003). Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol, 17, 12-16
23. Pettitt DJ, Talton J, Dabelea D, et al. (2014). Prevalence of diabetes in U.S. youth in 2009: The SEARCH for diabetes in youth study. Diabetes Care, 37, 402-8
24. Ray S, Sonthalia N, Kundu S, Ganguly S. (2012). Autoimmune disorders: An overview of molecular and cellular basis in todays perspective. J Clin Cell Immunol, S10, 003
25. Rigby MR, DiMeglio LA, Rendell MS, et al. (2013). Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol, 1, 284-94
26. Romi F. (2011). Thymoma in myasthenia gravis: From diagnosis to treatment. Autoimmune Dis, 2011, 474512
27. Salvi M, Vannucchi G, Currò N, et al. (2015). Efficacy of B-Cell targeted therapy with rituximab in patients with active moderate to severe graves orbitopathy: A randomized controlled study. J Clin Endocrinol Metab, 100, 422-31
28. Schwenger V, Morath C. (2010). Immunoadsorption in nephrology and kidney transplantation. Nephrol Dial Transplant, 25, 2407-13
29. Skyler JS, Ricordi C. (2011). Stopping type 1 diabetes: Attempts to prevent or cure type 1 diabetes in man. Diabetes, 60, 1-8
30. Tisch R, Liblau RS, Yang XD, et al. (1998). Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice. Diabetes, 47, 894-9
31. Waldner H. (2009). The role of innate immune responses in autoimmune disease development. Autoimmun Revs, 8, 400-4
32. Wherrett DK, Bundy B, DiMeglio LA, et al. (2011). Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: A randomized double-masked controlled trial. Lancet, 378, 319-27
33. Winthrop KL, Chiller T. (2009). Preventing and treating biologic-associated opportunistic infections. Nat Rev Rheumatol, 5, 405-10
34. Yanaba K, Bouaziz J-D, Matsushita T, et al. (2008). B-lymphocyte contributions to human autoimmune disease. Immunol Rev, 223, 284-99
35. Zhang YY, Tang Z, Chen DM, et al. (2014). Comparison of double filtration plasmapheresis with immunoadsorption therapy in patients with anti-glomerular basement membrane nephritis. BMC Nephrol, 15, 128